Embla Medical hf (OCSE:EMBLA) EPS (Basic): kr1.30 (TTM As of Mar. 2026)

What is Embla Medical hf EPS (Basic)?

Embla Medical hf OCSE:EMBLA -0.57% 92 EPS (Basic) is kr1.30 as of Mar. 2026. GuruFocus rates OCSE:EMBLA with a GF Score™ of 92/100 and a GF Value™ of kr34.32 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Embla Medical hf's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr0.22. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.30.

Embla Medical hf's EPS (Diluted) for the three months ended in Mar. 2026 was kr0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.30.

Embla Medical hf's EPS without NRI for the three months ended in Mar. 2026 was kr0.22. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 1.30.

During the past 12 months, Embla Medical hf's average EPS without NRIGrowth Rate was 10.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was 20.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 48.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Embla Medical hf's highest 3-Year average EPS without NRI Growth Rate was 238.30% per year. The lowest was -56.80% per year. And the median was 8.50% per year.

Embla Medical hf (OCSE:EMBLA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Embla Medical hf EPS (Basic) Related Terms

Embla Medical hf EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Embla Medical hf's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embla Medical hf EPS (Basic) Chart

Embla Medical hf Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

1.03

0.72

0.96

1.15

1.25

Embla Medical hf Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															0.19	0.32	0.38	0.37	0.22

92GF Score

Embla Medical hf OCSE:EMBLA

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Embla Medical hf EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Embla Medical hf's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(531.55	-	0)	/	426.959
	=	1.24

Embla Medical hf's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(93.469	-	0)	/	425.206
	=	0.22

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.30

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of kr1.30 mean?

Embla Medical hf (OCSE:EMBLA) has a EPS (Basic) of kr1.30 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Embla Medical hf and its competitors.

Is Embla Medical hf's EPS (Basic) too high?

Embla Medical hf's current EPS (Basic) is kr1.30. Overall, Embla Medical hf has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Embla Medical hf's EPS (Basic) compare to ABT and SYK?

Embla Medical hf's EPS (Basic) of kr1.30 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Medical Devices & Instruments company?

A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Embla Medical hf and its competitors. Embla Medical hf's current EPS (Basic) is kr1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Embla Medical hf stock overvalued right now?

Based on GuruFocus' analysis, Embla Medical hf (OCSE:EMBLA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.32, compared to a current price of kr25.95 — trading 24.4% below its estimated fair value. The current EPS (Basic) is kr1.30. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Embla Medical hf (OCSE:EMBLA), the current EPS (Basic) is kr1.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of kr25.95 is trading 24.4% below its estimated GF Value™ of kr34.32. GuruFocus considers Embla Medical hf to be Modestly Undervalued.

Key valuation signals for OCSE:EMBLA:

EPS (Basic): kr1.30
GF Value™: kr34.32 vs. price of kr25.95 (24.4% below fair value)
GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embla Medical hf Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OCSE:GN OCSE:CHEMM OCSE:AMBU B OCSE:VIRO OCSE:SMSMED OCSE:DEMANT ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA STE ZBH XSWX:SOON SHSE:688271

Other Exchanges 0FIW:UK 5IQ:Germany

Address Grjothals 5, Reykjavik, ISL

Website https://www.emblamedical.com

Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.

92GF Score

Get the complete analysis for OCSE:EMBLA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr25.95

Price

kr34.32

GF Value

View OCSE:EMBLA Analysis

See EPS (Basic) data for all stocks →